A substantial amount of evidence has shown dysregulation of FGFR signaling as a pathogenic mechanism and consequence of cancer,93 and it is frequently detected to be highly expressed in HCC, contributing to tumorigenesis, progression, and drug resistance.94,95 Despite the relatively low frequency of genetic alterations, dysregulated FGF/FGFR signaling affects about half of HCC patients.96–98 Among the FGF and FGFR families, currently the most studied and promising target in HCC is the FGF19-FGFR4 signaling pathway. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.